Chester County News and Community Website
RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) said it granted stock options and restricted stock units to a new non-executive employee on March 16 as an inducement to join …
Mineralys Grants Inducement Equity Awards to New Employee Read More RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) reported its fourth-quarter and full-year 2025 financial results and said the U.S. Food and Drug Administration has accepted its new drug application …
Mineralys Reports 2025 Results, Advances Hypertension Drug Review Read More RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) announced that its board compensation committee granted inducement stock option and restricted stock unit awards to two new non-executive employees on February …
Mineralys Therapeutics Grants Inducement Equity Awards to Two New Employees Read More RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) said this week it is approaching a pivotal stretch of clinical and regulatory milestones for lorundrostat, its lead drug candidate for difficult-to-treat …
Mineralys Flags Key Data Readouts as Lorundrostat Nears FDA Decision Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) said its Phase 3 Launch-HTN clinical trial evaluating lorundrostat was selected by JAMA editors as one of the most impactful medical studies …
JAMA Spotlights Mineralys Trial as Breakthrough for Resistant Hypertension Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) granted an inducement stock option covering 146,000 shares to a newly hired non-executive employee, the company said following a November 24 action …
Mineralys Awards New Hire Stock Option as Hypertension Pipeline Advances Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) reported third-quarter financial results and said it is preparing to submit a New Drug Application (NDA) for its lead candidate, lorundrostat, by …
Mineralys Nears Pivotal FDA Filing as Hypertension Drug Lorundrostat Advances Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced that new data from its Phase 2 Explore-CKD trial evaluating lorundrostat in patients with hypertension and chronic kidney disease (CKD) will …
Mineralys Therapeutics to Present Key Lorundrostat Data at ASN Kidney Week 2025 Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced it has completed enrollment in its Phase 2 EXPLORE-OSA trial evaluating lorundrostat in patients with moderate-to-severe obstructive sleep apnea (OSA) and …
Mineralys Completes Enrollment in Phase 2 Sleep Apnea and Hypertension Trial Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced new subgroup analyses from its Phase 3 Launch-HTN trial, showing that its investigational therapy lorundrostat significantly lowered blood pressure across multiple …
Mineralys Reports Strong Phase 3 Results for Lorundrostat in High-Risk Hypertension Patients Read More